ClinicalTrials.gg
RecruitingNCT07003139Updated May 13, 2026

A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors

A Phase 1/2 interventional study of B10 L-BPA Injection in Malignant Brain Tumors, sponsored by China Medical University Hospital. Recruiting at 2 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by China Medical University Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Brain Neoplasms with a site in Taiwan — 19 open to participants now, 20 under way, 2 of them phase 3. Brain Neoplasms · Taiwan.

Planned enrollment
36th of 41
10 · median 100
Started
2025
with 3 others
Phase 1/2
4 of 53
3 open now
Primary completion
2026-06
later than 7 of 19 live
Registered
50th of 53
by date
Lead sponsor
2 of 53
China Medical University Hospital

Among the 53 studies in Brain Neoplasms with a site in Taiwan, this one is the 36th largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 7 of the 19 other live ones, and was the 50th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

19 of the 53 studies in Brain Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Brain Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

This Phase I/II study, titled 'A Phase I/II Study to Evaluate Safety and Efficacy of the Boron Neutron Capture Therapy (BNCT) using B10 L-BPA as Boron Carrier in Malignant Brain Tumors.', aims to assess the efficacy of B10 L-BPA with BNCT in patients with malignant brain tumors. The primary objective is to evaluate the safety and efficacy of BNCT with B10 L-BPA for malignant brain tumors treatment, using the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) as the standard for assessment.

Read the detailed description

Not provided

03

Conditions studied

  • Malignant Brain Tumors

Browse trials for

Keywords

  • L-4-(10B)Boronophenylalanine
  • (10B)-4-Borono-L-phenylalanine
  • BNCT
  • Malignant Brain Tumors
  • Boron Neutron Capture Therapy
  • Borofalan (10B)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 18 years and older.
  2. Patients with malignant brain tumors confirmed by histological and/or medical imaging, classified as WHO Grade 3 or 4 according to the World Health Organization of tumors of the central nervous system (CNS) classification, excluding those with confirmed Grade 3 intracranial ependymoma, medulloblastoma, and primary CNS lymphoma.
  3. There must be a time interval ≥ 3 months between prior radiation therapy and the scheduled BNCT.
  4. There must be a time interval ≥ 1 month between receipt of antitumor drugs and the scheduled BNCT.
  5. Within 4 weeks prior to the screening visit, by magnetic resonance imaging (MRI) and/or computed tomography (CT) scan showing a volume ≦ 250 cm\^3, longest dimension \< 7 cm.
  6. At least one measurable lesion that can be assessed by v1.1.
  7. (ECOG) Performance Score ≤ 2.
  8. ≥ 3 months in the opinion of the investigator.
  9. Adequate organ functions as defined below:

    • ≥ 8.0 g/dL.
    • White blood cell (WBC) count ≥ 2.5 x 10\^3/μL.
    • ≥ 1.5 × 10\^3/μL.
    • count ≥ 80 × 10\^3/μL.
    • (AST) ≤ 2.5 × (ULN).
    • Alanine aminotransferase (ALT) ≤ 2.5 × ULN.
    • Serum creatinine ≤ 1.5 × ULN
    • Estimated (eGFR) ≥ 15 mL / min / 1.73m\^2
  10. Female subjects with must have a negative result of serum pregnancy test at the screening visit and urine pregnancy test before the B10 L-BPA administration. However, if the subject has been menopausal for at least 2 years (more than 24 months since the last menstrual period) or uses surgical , testing is not required.
  11. Female subject with as well as male subject with reproductive potential must agree to refrain from unprotected sex and use 2 methods of highly effective contraception with their partner (e.g. barrier contraceptives [male condom, female condom, or diaphragm plus spermicide], intrauterine device, hormonal methods [hormone shot or injection, implants, combination oral contraceptives, or patches]) for ≥ 6 months after the BNCT until the end of this study.
  12. Physically and mentally capable of participating in the study and willing to adhere to study procedures.
  13. Provision of signed .

Exclusion criteria

Exclusion Criteria:

  1. Patients with malignant brain tumors complicated by any of the following conditions:

    • Extracranial .
    • Multiple intracranial lesions on both sides.
  2. The investigator assesses that the subject has concurrent infections or other malignant tumors and is not suitable to participate in the trial.
  3. Patients with malignant brain tumors are considered eligible for standard surgical treatment that is effective against the tumor.
  4. A time interval less than 3 months from previous radiation therapy for intracranial region.
  5. A time interval less than 3 months from last brain surgery (excluding drainage procedures and ) and less than 1 month from previous chemotherapy.
  6. The adverse event of previous anti-tumor therapy were V5.0 grade evaluation ≧ Class 3 (excluding alopecia and peripheral neuropathy).
  7. Received or expect to receive any drug, biologic or device within 1 month prior to the scheduled BNCT.
  8. Patients receiving or expected to receive vascular endothelial growth factor inhibitors (except bevacizumab) or within 1 month prior to the scheduled BNCT.
  9. Patients received major surgery within 1 month prior to the scheduled BNCT or are still recovering from a previous surgery. The investigator will evaluate the subject's condition when the subject receives major surgery. Major surgery is defined as procedure that requires general anaesthesia and/or anticipated hospitalization longer than 24 hours, with significant risk of blood loss or complications. Examples include heart surgery, organ transplants, and prolonged operations such as certain back surgeries. Procedures such as stent implantation, biopsy, endoscopy, and day surgery are excluded.
  10. Patients who had radiation myelitits or radiation necrosis of the brain/brain stem.
  11. Patient who is prone to vascular rupture during the trial as assessed by the investigator. The Patient will be eligible for the study if they have undergone stent implantation and obtained consent from the investigator.
  12. Patients with severe congestive heart failure or renal failure, as well as myocardial infarction, unstable angina, or poorly controlled arrhythmia within 6 months prior to the scheduled BNCT.
  13. Severe comorbidities, including but not limited to poorly controlled epilepsy, poorly controlled diabetes mellitus, poorly controlled hypertension; chronic lung diseases (e.g., obstructive pneumonia, interstitial pneumonia, pulmonary fibrosis, and severe emphysema); kidney diseases (e.g., chronic renal failure, acute renal failure and nephrotic syndrome); cardiac diseases (e.g., [NYHA] Functional Classification Class III or IV); phenylketonuria; and/or other severe conditions in the opinion of the investigator.
  14. Suspected or known (including allergy) to boron or any component of the study drug or contrast media.
  15. Subject with hereditary fructose intolerance.
  16. With a cardiac pacemaker or will interfere with MRI-based or CT-based dose-planning or tumor response evaluation.
  17. Restless subjects who are unable to lie or sit in a cast for more than 30 minutes.
  18. Any medical or psychiatric conditions that, in the opinion of the investigator, may interfere with optimal participation in the study or place the subject at increased risk of adverse events (AEs).
  19. Female subject who is planning to be pregnant or lactating during the study period.
  20. Subject who is considered unfit to participate in the clinical study as assessed by the investigator.
  21. Subject who has received prior BNCT.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Boron Neutron Capture Therapy

    Single arm treated by BNCT only

    Drug: B10 L-BPA Injection

Interventions

  • DrugB10 L-BPA Injection

    The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.

06

What researchers measure

Primary outcomes

  1. Safety of BNCT using B10 L-BPA in treating malignant brain tumors

    Safety will be assessed by monitoring the occurrence, severity, and relationship of treatment-emergent adverse events (TEAEs), including serious adverse events and events leading to permanent discontinuation of therapy, according to protocol definitions and CTCAE v5.0.

    Time frame: 6 months

  2. Efficacy of BNCT using B10 L-BPA in treating malignant brain tumors

    Efficacy of BNCT with B10 L-BPA for treating malignant brain tumors will be assessed by the percentage of subjects achieving complete response (CR) and partial response (PR). Tumor response will be evaluated using RECIST v1.1 criteria via high-resolution CT or MRI.

    Time frame: 6 months

Secondary outcomes

  1. Progression-free survival

    PFS is defined as the time from receiving the B10 L-BPA-based BNCT until progressive disease (PD) or death from any cause, whenever comes the first. PFS is evaluated by imaging according to the RECIST v1.1 criteria.

    Time frame: 6 months

  2. Change in Quality of Life as Measured by the EORTC QLQ-C30 Questionnaire

    The EORTC QLQ-C30 is a validated questionnaire that evaluates cancer patients' quality of life through functional, symptom, and global health scales. It primarily using a 4-point scale (1='Not at All' to 4='Very Much'), and a 7-point scale for two items, where higher scores indicate more symptoms.

    Time frame: 6 months

  3. Change in Quality of Life as Measured by the EORTC QLQ-BN20 Questionnaire

    The EORTC QLQ-BN20 is a validated module for brain tumor patients that assesses disease- and treatment-specific symptoms such as motor dysfunction, communication issues, and visual or cognitive changes. It uses a 4-point scale (1 = "Not at All" to 4 = "Very Much"), where higher scores indicate more severe symptoms.

    Time frame: 6 months

Other outcomes

  1. The population of circulating immune cells

    Blood samples will be collected to assess MDSCs, T cells and IL-1β at multiple time points: before and after BNCT. This approach aims to clarify whether the levels of circulating immune cells could serve as prognostic indicators for BNCT treatment outcomes.

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 51 non-industry phase 1/2 interventional studies under Brain Neoplasms, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 105. This study's planned 12 months is below that.

Counting every sponsor, half of 74 studies reached it within 85 months; a quarter within 49 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
Jun 4, 2025
StartActual
Jun 30, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07003139
Collaborators
Heron Neutron Medical Corp.
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Jun 30, 2025
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion